Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OEM moves into reprocessing

This article was originally published in The Gray Sheet

Executive Summary

Orthopedic firm Synthes is offering hospitals the option to reprocess used external fixation devices as part of a new reprocessing program. The U.S. division of the Swiss firm is reprocessing over a dozen of its fixation devices, including single-use devices such as its "combination clamp"and "tube to tube clamps," according to a marketing document. Dan Vukelich of the Association for Medical Device Reprocessors says that the fact that an original manufacturer is reprocessing single-use devices is an "implicit acknowledgement that reprocessing is here to stay because it allows hospitals to achieve substantial savings without sacrificing the quality of the care they deliver." Orthopedic makers such as Smith & Nephew have lobbied for stringent regulation of reprocessing on the grounds that reprocessed single-use devices pose a risk to patients (1"The Gray Sheet" Oct. 24, 2005, p. 27)...

You may also be interested in...

Massachusetts Bill Seeks Informed Consent, Liability For Reused Devices

A pending bill that requires informed consent before a doctor can use a reprocessed single-use device could be taken up by the Massachusetts House of Representatives in early 2006

Big Win For EMA On Transparency

The European Court of Justice has confirmed the European Medicines Agency’s approach to disclosure of data submitted as part of a marketing authorization application. It is a big disappointment for industry, which nonetheless says it supports responsible data sharing and will support efforts to develop a balanced approach.

UK Biotech Financing Holds Up Despite Woodford and Brexit

Neil Woodford’s fall from grace and Brexit dragged on an otherwise buoyant sector



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts